1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
AVITA Medical, Inc.

AVITA Medical, Inc.

AVH.AX
AVITA Medical, Inc.AU flagAustralian Securities Exchange
1.41
AUD
-0.03
- -
174.52MMarket Cap
AVITA Medical, Inc.
AVH.AX
(Australian Securities Exchange)

Recent

price

1.41

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.38
0.51
0.25
0.15
0.14
0.11
0.03
0.02
0.02
0.09
0.14
0.26
0.28
0.4
0.5
0.51
0.5
Revenue per Share
-0.84
-0.29
-0.58
-0.43
-0.26
-0.27
-0.21
-0.24
-0.27
-0.4
-0.41
-0.23
-0.21
-0.28
-0.48
-0.35
-0.31
Basic EPS, GAAP
-0.28
-0.46
-0.32
-0.43
-0.38
-0.32
-0.21
-0.18
-0.28
-0.32
-0.23
-0.24
-0.16
-0.31
-0.45
-0.23
-0.22
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.22
2.07
0.38
0.4
0.25
0.14
0.14
0.05
0.22
-2.41
-1.92
-1.95
-2.1
-2.35
-2.78
-2.93
-2.9
Book Value per Share
0.21
2.2
0.64
0.56
0.28
0.16
0.18
0.11
0.3
0.33
0.71
1.02
0.67
0.38
-0.01
-0.16
-0.2
Tangible Book Value per Share
6
7
13
17
18
20
28
37
47
63
101
113
125
127
129
139
145
Basic Weighted Avg Shares
2
3
3
3
3
2
1
1
1
5
14
29
34
50
64
72
72
Sales/Revenue/Turnover
-135.71
-160.6
-209.69
-335.99
-269.39
-290.53
-1,134.12
-1,430.17
-1,489.88
-466.35
-299.23
-90.79
-79.91
-85.07
-88.08
-59.4
-54.62
Operating Margin (%)
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
2
2
Depreciation Expense
-5
-2
-8
-7
-5
-5
-6
-9
-13
-25
-42
-27
-27
-35
-62
-49
-45
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-222.75
-57.58
-226.42
-287.49
-191.84
-258.44
-776.24
-1,277.05
-1,370.83
-458.57
-294.68
-90.94
-77.47
-70.56
-96.26
-67.85
-62.67
Profit Margin (%)
4
14
9
9
5
3
5
4
14
20
71
114
77
91
37
-27
-35
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
1
- -
42
45
2
2
LT Debt
4
17
9
10
5
3
5
4
14
21
72
116
85
49
4
-17
-23
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-178.65
-25.79
-83.31
-124.03
-85.3
-149.2
-175.98
-302.99
-204.98
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
42
44
46
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
31
31
Market Capitalization
217
146
156

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
41
35
32
Cash, Cash Equivalents & STI
23
18
14
Accounts Receivable, Net
9
9
10
Inventories
7
7
6
Total Current Liabilities
62
63
67
Payables & Accruals
14
17
15
ST Debt
42
44
46
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.65%
-114%
-470.08%
Free Cash Flow
26.17%
18.29%
-44.57%
Net Income, GAAP
31.7%
9.92%
-21.44%
Sales/Revenue/Turnover
81.99%
41.59%
11.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11
15
20
18
64
2025
19
18
17
18
72
2026
19
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.15
-0.12
-0.12
-0.09
-0.48
2025
-0.11
-0.08
-0.09
-0.08
-0.35
2026
-0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Drägerwerk AG & Co. KGaA (DRW3.DE)
Cochlear Limited (CHEOY)
Nemaura Medical Inc. (NMRD)
FUJIFILM Holdings Corporation (FJI.F)
Epitomee Medical Ltd (EPIT.TA)
Colan Totte.Co.,Ltd. (7792.T)
Business
AVITA Medical, Inc. (ASX:AVH) develops and commercializes regenerative medicine technologies for wound care management and skin restoration, including its flagship RECELL System, a patented point-of-care device that produces Spray-On Skin Cells from a patient's own skin for treating thermal burns, full-thickness skin defects, trauma and surgical wounds; PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a collagen-based dermal matrix, with the recently FDA-approved RECELL GO System enhancing application efficiency as a primary wound dressing. Founded in 1992 as Clinical Cell Culture in Perth, Australia, and now headquartered in Valencia, California, the company operates primarily in the United States across approximately 136 burn centers and high-value facilities targeting burns, trauma, vitiligo and aesthetics indications, while expanding internationally to Europe, Australia, New Zealand, Asia-Pacific and Canada. In recent developments, AVITA Medical received CE Mark approval in September 2025 for RECELL GO to enable launches in Germany, Italy and the United Kingdom; entered an exclusive distribution agreement with Revolution Surgical Pty Ltd in November 2024 to reintroduce RECELL products in Australia and New Zealand; restored U.S. reimbursement clarity through finalized Medicare payment rates under new Category I CPT codes across all regional contractors; and reported third-quarter 2025 commercial revenue of US$17.1 million with narrowed net losses, revised full-year revenue guidance to US$70-74 million, and ongoing cost efficiencies reducing operating expenses by 24 percent year-over-year.

Company News

APIChatGPT

  • globenewswire.com

    AVITA Medical to Host Investor Webinar Briefing

  • globenewswire.com

    AVITA Medical to Host Investor Webinar Briefing

  • globenewswire.com

    Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies